Introduction to Ibrance Treatment
Ibrance, also known as palbociclib, is a targeted therapy medication used in the treatment of hormone receptor-positive, HER2-negative breast cancer. It is classified as a CDK4/6 inhibitor, which means it works by blocking specific proteins in cancer cells that help them grow and divide.
Mechanism of Action
Ibrance works by inhibiting CDK4 and CDK6, two proteins that are important for cell cycle progression. By blocking these proteins, Ibrance slows down the growth of cancer cells, preventing them from dividing and proliferating.
Dosage and Administration
The recommended dose of Ibrance for breast cancer treatment is usually taken orally once daily for 21 days, followed by a week off. It is important to follow the prescribed dosage and schedule as directed by your healthcare provider.
Side Effects
Common side effects of Ibrance may include fatigue, nausea, hair loss, and decreased appetite. More serious side effects can occur, so it is important to report any unusual symptoms to your healthcare provider.
Effectiveness in Seniors
Studies have shown that Ibrance can be effective in treating breast cancer in seniors, especially those with hormone receptor-positive tumors. However, the safety and efficacy of Ibrance in older patients may vary, so individualized treatment plans are essential.
Cost and Insurance Coverage
Ibrance can be an expensive medication, and insurance coverage may vary depending on the individual's plan. There are patient assistance programs and financial resources available to help offset the cost of Ibrance treatment.